Please login to the form below

Not currently logged in

Ex J&J VP joins board of Immune

Cameron Durrant also has senior experience at Pharmacia
cameron durrant immune

Immune Pharmaceuticals has added veteran pharma experience to its board with the appointment of Cameron Durrant.

Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson & Johnson and VP, Pharmacia until its acquisition by Pfizer.

His other experience includes serving as CEO of PediatRx and CEO of PediaMed Pharmaceuticals as part of a career in pharma that began at Merck & Co.

Dr Daniel Teper, Immune's chairman and CEO, commented: "I have been privileged to work with Cameron in several of his leadership roles at GSK, Pharmacia, J&J and PediaMed.

“His entrepreneurial drive along with the discipline acquired at leading companies and his extensive board experience at public and private companies will be a strong asset as Immune expands its clinical development and commercialisation activities."

Immune specialises in developing antibodies to treat patients with inflammatory diseases and cancer. Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.

21st July 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge